In last trading session, Elevation Oncology Inc (NASDAQ:ELEV) saw 0.62 million shares changing hands with its beta currently measuring 1.38. Company’s recent per share price level of $4.73 trading at -$0.21 or -4.25% at ring of the bell on the day assigns it a market valuation of $230.11M. That closing price of ELEV’s stock is at a discount of -24.52% from its 52-week high price of $5.89 and is indicating a premium of 92.39% from its 52-week low price of $0.36. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.05 million shares which gives us an average trading volume of 1.67 million if we extend that period to 3-months.
Elevation Oncology Inc (NASDAQ:ELEV) trade information
Upright in the red during last session for losing -4.25%, in the last five days ELEV remained trading in the red while hitting it’s week-highest on Thursday, 04/11/24 when the stock touched $4.73 price level, adding 5.02% to its value on the day. Elevation Oncology Inc’s shares saw a change of 780.82% in year-to-date performance and have moved -3.67% in past 5-day. Elevation Oncology Inc (NASDAQ:ELEV) showed a performance of 13.43% in past 30-days. Number of shares sold short was 5.01 million shares which calculate 4.2 days to cover the short interests.
Elevation Oncology Inc (ELEV) estimates and forecasts
Statistics highlight that Elevation Oncology Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 605.97% of value to its shares in past 6 months, showing an annual growth rate of 35.07% while that of industry is 13.30. Apart from that, the company came raising its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to increase by 72.20% in the current quarter and calculating 43.20% increase in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -52.56% during past 5 years.
ELEV Dividends
Elevation Oncology Inc is more likely to be releasing its next quarterly report in May and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Elevation Oncology Inc (NASDAQ:ELEV)’s Major holders
Insiders are in possession of 1.97% of company’s total shares while institution are holding 86.30 percent of that, with stock having share float percentage of 88.03%. Investors also watch the number of corporate investors in a company very closely, which is 86.30% institutions for Elevation Oncology Inc that are currently holding shares of the company. Tang Capital Management, LLC is the top institutional holder at ELEV for having 4.0 million shares of worth $6.08 million. And as of Jun 29, 2023, it was holding 9.44% of the company’s outstanding shares.
The second largest institutional holder is venBio Partners LLC, which was holding about 2.91 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 6.88% of outstanding shares, having a total worth of $4.43 million.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jun 29, 2023, the former fund manager was holding 0.85 million shares of worth $1.3 million or 2.02% of the total outstanding shares. The later fund manager was in possession of 0.2 million shares on Jun 29, 2023, making its stake of worth around $0.31 million in the company or a holder of 0.48% of company’s stock.
